

Osteonecrosis of the jaw in cancer patients in association with bevacizumab, Avastin▼ and concomitant or previous use of bisphosphonates

30th November 2010

Dear Healthcare Professional

Summary

Roche Products Limited would like to inform you of an important update to the safety information regarding the use of AVASTIN (bevacizumab).

Cases of osteonecrosis of the jaw (ONJ) have been reported in cancer patients in association with Avastin treatment, the majority of whom had received prior or concomitant treatment with i.v. bisphosphonates.

Avastin treatment may be an additional risk factor for the development of osteonecrosis of the jaw.

This potential risk should be particularly considered when Avastin and bisphosphonates are administered simultaneously or sequentially.

Dental examination and appropriate preventive dentistry should be considered prior to treatment with Avastin. In patients who have previously received or are receiving i.v. bisphosphonates invasive dental procedures should be avoided, if possible.

The communication of this information has been agreed with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA).

Roche Products Limited RXUKAVAS00043 November 2010	6 Falcon Way, Shire Park Welwyn Garden City Herts AL7 1TW Registered in England No. 100674	Medical Information	Tel. 0800 328 1629 Email: medinfo.uk@roche.com.
--	--	---------------------	--

Further information on the safety concern

To date, it has been estimated that Avastin has been administered to more than 800,000 cancer patients.

A cumulative analysis of the company safety database, ADVENT, which includes data from clinical trials as well as spontaneous adverse drug reaction reports identified 55 cases of osteonecrosis of the jaw. Reporting rates appear to be low, less than 1 in 10,000 patients.

The majority of cases were confounded by concurrent chemotherapy and concomitant or previous bisphosphonate treatment. Many patients had also received other treatments which are known risk factors for osteonecrosis/osteonecrosis of the jaw (e.g., radiotherapy, glucocorticoids).

The occurrence of osteonecrosis of the jaw has been linked to bisphosphonate treatment. Bisphosphonates have very long half-lives and may remain active in bone tissue for many months after discontinuation of therapy.

Avastin has anti-angiogenic activity and this mechanism is currently under investigation for potential impact on the clinical course of osteonecrosis of the jaw.

The Summary of Product Characteristics for Avastin is being updated to include new safety information on osteonecrosis of the jaw (ONJ), as follows:

4.4 Special warnings and precautions for use

Cases of ONJ have been reported in cancer patients treated with Avastin, the majority of whom had received prior or concomitant treatment with i.v. bisphosphonates, for which ONJ is an identified risk. Caution should be exercised when Avastin and i.v. bisphosphonates are administered simultaneously or sequentially.

Invasive dental procedures are also an identified risk factor. A dental examination and appropriate preventive dentistry should be considered prior to starting the treatment with Avastin. In patients who have previously received or are receiving i.v. bisphosphonates invasive dental procedures should be avoided, if possible.

4.8 Undesirable Effects

Cases of osteonecrosis of the jaw (ONJ) have been reported in patients treated with Avastin, most of which occurred in patients, who had identified risk factors for ONJ, in particular exposure to i.v. bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4).

RXUKAVAS00043 November 2010

Call for reporting

Healthcare professionals should report any serious adverse events suspected to be associated with the use of Avastin to Roche by phone on 01707 367554, by fax on 01707 367582 or e-mail at welwyn.uk_dsc@roche.com.

Any suspected adverse reaction should also be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using a Yellow Card available directly from the MHRA, FREEPOST YELLOW CARD or electronically via the MHRA website at <http://www.yellowcard.gov.uk>.

For further information or any questions on ONJ associated with the use of Avastin, please contact Roche Medical Information on 0800 328 1629 or 01707 361 010 or e-mail at medinfo.uk@roche.com.

Yours sincerely,



Dr Julian Cole
Head of Medical Affairs

RXUKAVAS00043 November 2010